[Subacute cutaneous lupus erythematosus and interferon beta-1 a].
Schmutz
J
J
Service de Dermatologie, Hôpital Fournier, 54000 Nancy, France.
Barbaud
A
A
Tréchot
P
P
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a